股票代码：688767 证券简称：博拓生物 公告编号：2025-035 杭州博拓生物科技股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州博拓生物科技股份有限公司（以下简称"公司"）于2025年5月16日召开2024 年年度股东大会，审议通过了《关于2024年年度利润分配及资本公积转增股本预案的议 案》，权益分派已于2025年6月6日实施完毕。具体内容详见公司于2025年5月30日在上 海证券交易所网站（www.sse.com.cn）披露的《杭州博拓生物科技股份有限公司2024 年年度权益分派实施公告》（公告编号：2025-031）。 1 产租赁；园区管理服务；货物进出口；技术进出口；工程和技术研究和试验发展；计算 机软硬件及外围设备制造；信息技术咨询服务；电子真空器件制造；信息安全设备销售； 电子元器件零售；电子真空器件销售；电力电子元器件销售；信息安全设备制造；第二 类医疗设备租赁；计算器设备销售；电力电子元器件制造；电子元器件制造；电子专用 材料制造；集成电路 ...

Group 1 - A total of 24 companies were investigated by institutions on June 25, with 17 companies specifically targeted by funds [1][2] - The most popular company among funds was Botao Bio, which had 21 participating funds, followed by Sanfu Outdoor and Entropy Technology with 7 and 6 funds respectively [1][2] - The companies investigated belong to 12 different industries, with the textile and apparel, and pharmaceutical and biotechnology sectors having the most companies, each with 3 stocks listed [1] Group 2 - Among the companies investigated, 3 had a total market capitalization exceeding 50 billion yuan, while 13 had a market cap below 10 billion yuan [1] - In terms of market performance, 9 stocks among the investigated companies saw an increase in the last 5 days, with Haike Xinyuan, Bai'ao Intelligent, and Ganfeng Lithium leading with increases of 50.83%, 10.42%, and 5.88% respectively [1][2] - Conversely, 8 stocks experienced declines, with Mankalon, Botao Bio, and China Merchants Energy showing the largest drops of 7.94%, 5.35%, and 4.76% respectively [1][2]

Summary of the Conference Call on Botao Bio Industry Overview - **Industry**: Brain-Computer Interface (BCI) Technology - **Company**: Botao Bio - **Investment**: Acquired a 5% stake in Qingchuang Vision, a brain-computer interface company focused on depression treatment, leveraging technology from Zhejiang University [2][3] Key Points and Arguments - **Strategic Shift**: Botao Bio aims to transition from diagnostics to integrated diagnosis and treatment, particularly in the BCI sector [2][4] - **Government Support**: The Chinese government has prioritized BCI technology, allocating over 30 billion for development by 2030, with an additional 16.8 billion planned for the coming years [2][5] - **Market Potential**: The BCI technology market is vast, with over 1 billion patients suffering from major brain diseases in China, including nearly 100 million with depression [3][15] - **Technological Distinction**: BCI technology is categorized into invasive (high signal quality, up to 50 kHz) and non-invasive (lower signal quality) methods, with applications in rehabilitation and treatment of severe brain diseases [2][7][9] - **Research Landscape**: BCI research is primarily conducted in universities and research institutions, with leading companies like Zhiruan and Xingdao at the forefront [10] Additional Important Content - **Clinical Applications**: Current applications of BCI technology include rehabilitation for motor functions and sensory restoration, with significant room for growth in treating major brain diseases [9][15] - **Challenges in Development**: Invasive BCI technology faces high barriers due to its interdisciplinary nature, requiring collaboration across fields such as computer science, materials science, and clinical medicine [13] - **Unique Technologies**: Botao Bio has developed three core technologies for depression treatment, focusing on precise implantation, real-time emotional state monitoring, and closed-loop stimulation adjustment [19] - **Collaborations**: The company has established partnerships with Zhejiang University’s affiliated hospitals for clinical trials and research [21] - **Future Directions**: Plans for product development include a second-generation device with self-developed chips, aiming for clinical trials and eventual market release by 2029 [24][28] Market Dynamics - **DBS System Comparison**: Botao Bio's deep brain stimulation (DBS) system is designed to record, stimulate, and compute, differentiating it from existing products in the market [27] - **Patient Acceptance**: There is a high demand for new therapies among treatment-resistant depression patients, indicating a favorable market environment for innovative solutions [29] - **Regulatory Landscape**: The company anticipates regulatory approval for its DBS system by 2029, with a focus on personalized treatment approaches [28] Conclusion - **Investment Opportunity**: The BCI sector, particularly in depression treatment, presents significant investment potential driven by government support, technological advancements, and a large patient population in need of innovative therapies [2][5][15]

Group 1 - The company has been deeply engaged in the POCT (Point-of-Care Testing) sector since its establishment in 2008, offering a comprehensive range of products across five major testing fields: drug abuse detection, infectious disease detection, reproductive health detection, tumor marker detection, and myocardial marker detection [1] - The core product series, including drug detection and infectious disease detection, accounted for approximately 80% of total revenue in the first three quarters of 2023, driven by stable market growth and a well-established product layout [1] - The company has obtained a total of 743 certifications, including 50 domestic NMPA product registration certificates, 622 EU CE certifications, 3 US FDA 510(k) certificates, and 68 certifications from other countries and regions [1] Group 2 - The self-developed microfluidic immunofluorescence analysis system offers high sensitivity, simultaneous multi-item detection, ease of operation, and cost-effectiveness, filling market gaps and partially replacing the immunofluorescence detection market [2] - The strategic investment in the brain-computer interface company, Qingstone Yongjun, aims to leverage the company's financial reserves, targeting treatment for treatment-resistant severe depression, which affects about 30% of global depression patients, indicating significant market potential [2] - Revenue projections for the company are estimated at 602 million, 752 million, and 916 million yuan for 2025-2027, with corresponding net profits of 147 million, 183 million, and 224 million yuan, reflecting a favorable growth outlook [2]

Group 1 - The company held its second extraordinary general meeting of shareholders on June 4, 2025, to elect the fourth board of directors, which includes three non-independent directors and three independent directors, along with one employee representative director [1][2] - The newly elected board of directors will serve a term of three years starting from the date of the meeting [1] - Chen Yinlong was elected as the chairman of the fourth board of directors, and various specialized committees were established, including the Strategy Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee [2] Group 2 - The company appointed Wu Shujing as the general manager and Chen Yujie, Ye Chunsheng, and Liu Chao as vice general managers, with Fei Qijun appointed as the vice general manager and board secretary, and Yu Miaomiao as the financial officer [3][4] - All appointed senior management personnel meet the qualifications required for their positions and comply with relevant laws and regulations [4][7] - Huang Yufeng was appointed as the securities affairs representative to assist the board secretary [3][4] Group 3 - The third board of directors' independent director Wang Wenming and non-independent director Gao Hongmei will no longer serve after the completion of the board transition [5] - The company will no longer have a supervisory board, and its functions will be assumed by the audit committee of the board of directors [5]

Meeting Details - The shareholders' meeting of Hangzhou Botao Biological Technology Co., Ltd. was held on June 4, 2025 [1] - The meeting took place at a designated location in Hangzhou [1] - A total of 43 ordinary shareholders attended, holding 49,053,096 voting rights, which represents 45.9872% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved, with 99.9035% of votes in favor, 0.0877% abstaining, and 0.0088% against [1] - The cumulative voting results included the election of Chen Yinlong, Chen Yujie, and Wu Shujian as non-independent directors, with their respective votes confirming their election [2] Independent Directors Election - Wang Liang and Duan Jianping were elected as independent directors of the fourth board [2] - The voting for these independent directors also met the required thresholds for approval [2] Legal Compliance - The meeting's convening and proceedings were confirmed to comply with legal and regulatory requirements, ensuring the legitimacy of the participants and voting processes [3]

Core Viewpoint - The legal opinion letter from Zhejiang Tiance Law Firm confirms the legality and validity of the procedures and results of the second extraordinary general meeting of shareholders for Hangzhou Botao Biotechnology Co., Ltd. in 2025 [1][11]. Group 1: Meeting Procedures - The meeting was convened following the approval of the board of directors on May 19, 2025, and the notice was published on May 20, 2025, on the Shanghai Stock Exchange and other platforms [2][3]. - The meeting is scheduled for June 4, 2025, at 14:00, with specific voting times for online participation [3]. Group 2: Agenda and Voting - The agenda includes proposals to cancel the supervisory board, expand the business scope, amend the company’s articles of association, and elect new board members [2][4]. - A total of 43 shareholders (or their proxies) attended the meeting, representing 49,053,096 voting shares, which is 45.9872% of the total voting shares [5]. Group 3: Voting Results - All proposed resolutions were approved by the shareholders, with significant support for each item, such as 99.9035% approval for the proposal to amend the articles of association [6][10]. - The election of non-independent and independent directors received unanimous support, with no votes against any of the candidates [8][9].

Core Points - The company held its first meeting of the fourth board of directors on June 4, 2025, where all directors unanimously agreed to waive the notice period for the meeting [1] - Chen Yinlong was elected as the chairman of the fourth board of directors, with a unanimous vote of 7 in favor [1] - The board also elected members for various specialized committees, with Chen Yinlong serving as the convener of the strategic committee and other members appointed accordingly [2] - Wu Shujing was appointed as the general manager of the company, with a unanimous vote of 7 in favor [3] - Four individuals, including Chen Yujie and Ye Chunsheng, were appointed as deputy general managers, also with a unanimous vote of 7 in favor [4] - Yu Miaomiao was appointed as the financial officer, receiving unanimous support from the board [4] - Fei Qijun was appointed as the secretary of the board, with unanimous approval [5] - Huang Yufeng was appointed as the securities affairs representative, also with unanimous support from the board [5]

股票代码：688767 证券简称：博拓生物 公告编号：2025-034 杭州博拓生物科技股份有限公司 关于完成董事会换届选举及聘任高级管理人员、 证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州博拓生物科技股份有限公司（以下简称"公司"或"博拓生物"）于2025年6 月4日召开2025年第二次临时股东会，选举产生的第四届董事会成员，与公司于2025 年5月19日召开的职工代表大会选举的职工代表董事共同组成第四届董事会。同日，公 司召开第四届董事会第一次会议，审议通过了选举公司董事长、各专门委员会委员、 聘任第四届高级管理人员和证券事务代表等相关议案。现将具体情况公告如下： 一、董事会换届选举情况 （一）董事选举情况 2025 年 5 月 19 日，公司召开职工代表大会选举叶春生先生为公司第四届董事会职 工代表董事。2025 年 6 月 4 日，公司召开 2025 年第二次临时股东会，审议通过了《关 于董事会换届选举暨选举第四届董事会非独立董事的议案》《关于董事会换届选举暨选 举第四届董事会独立董事的 ...

本次会议是否有被否决议案：无 一、 会议召开和出席情况 杭州博拓生物科技股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （一） 股东会召开的时间：2025 年 6 月 4 日 （二） 股东会召开的地点：杭州市余杭区仓前街道途义路 27 号 A 幢 110 室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 证券代码：688767 证券简称：博拓生物 公告编号：2025-032 | 1、出席会议的股东和代理人人数 | 43 | | --- | --- | | 普通股股东人数 | 43 | | 2、出席会议的股东所持有的表决权数量 | 49,053,096 | | 普通股股东所持有表决权数量 | 49,053,096 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 45.9872 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 45.9872 | （四） 表决方式是否 ...